Mesenchymal stem cells and cardiomyocytes interplay to prevent myocardial hypertrophy

Stem Cells Translational Medicine

Volumn 4, Issue 12, 2015, Pages 1425-1435

  Cai, Benzhi ^a   Tan, Xueying ^a   Zhang, Yong ^a   Li, Xingda ^a   Wang, Xinyue ^a   Zhu, Jiuxin ^a   Wang, Yang ^a   Yang, Fan ^a   Wang, Baoqiu ^a   Liu, Yanju ^a   Xu, Chaoqian ^a   Pan, Zhenwei ^a   Wang, Ning ^a   Yang, Baofeng ^a,b   Lua, Yanjie ^b  

^a BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^b HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Cardiomyocyte; Crosstalk; Hypertrophy; Mesenchymal stem cell; Remodeling

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; SMALL INTERFERING RNA; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; CALCINEURIN; ISOPRENALINE; TRANSCRIPTION FACTOR NFAT; VASCULAR ENDOTHELIAL GROWTH FACTOR A, RAT; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW DERIVED MESENCHYMAL STEM CELL; CELL TRANSPLANTATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; MALE; NONHUMAN; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANIMAL; BONE MARROW CELL; CALCIUM SIGNALING; CARDIAC MUSCLE CELL; CARDIOMEGALY; CHEMICALLY INDUCED; COCULTURE; DRUG EFFECTS; MESENCHYMAL STROMA CELL; METABOLISM; SPRAGUE DAWLEY RAT;

ANIMALS; BONE MARROW CELLS; CALCINEURIN; CALCIUM SIGNALING; CARDIOMEGALY; COCULTURE TECHNIQUES; ISOPROTERENOL; MALE; MESENCHYMAL STROMAL CELLS; MYOCYTES, CARDIAC; NFATC TRANSCRIPTION FACTORS; RATS; RATS, SPRAGUE-DAWLEY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84949636644     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.5966/sctm.2015-0032     Document Type: Article

References (40)

1. Laflamme MA, Murry CE. Heart regeneration. Nature 2011;473:326–335.
2. Perin EC, López J. Methods of stem cell delivery in cardiac diseases. Nat Clin Pract Cardiovasc Med 2006;3(suppl 1):S110–S113.
3. Toma C, Pittenger MF, Cahill KS et al. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation 2002;105:93–98.
4. Ripa RS, Haack-Sørensen M, Wang Y et al. Bone marrow derived mesenchymal cell mobilization by granulocyte-colony stimulating factor after acute myocardial infarction: Results from the Stem Cells in Myocardial Infarction (STEMMI) trial. Circulation 2007;116(suppl): I24–I30.
5. Volarevic V, Arsenijevic N, Lukic ML et al. Concise review: Mesenchymal stem cell treatment of the complications of diabetes mellitus. STEM CELLS 2011;29:5–10.
6. Zhang N, Li J, Luo R et al. Bone marrow mesenchymal stem cells induce angiogenesis and attenuate the remodeling of diabetic cardiomyopathy. Exp Clin Endocrinol Diabetes 2008;116:104–111.
7. Nagaya N, Kangawa K, Itoh T et al. Transplantation of mesenchymal stem cells improves cardiac function in a rat model of dilated cardiomyopathy. Circulation 2005; 112:1128–1135.
8. Hahn JY, Cho HJ, Kang HJ et al. Pretreatment of mesenchymal stem cells with a combination of growth factors enhances gap junction formation, cytoprotective effect on cardiomyocytes, and therapeutic efficacy for myocardial infarction. J Am Coll Cardiol 2008; 51:933–943.
9. Frey N, Olson EN. Cardiac hypertrophy: The good, the bad, and the ugly. Annu Rev Physiol 2003;65:45–79.
10. Kehat I, Molkentin JD. Molecular pathways underlying cardiac remodeling during pathophysiological stimulation. Circulation 2010;122:2727–2735.
11. Kang YJ. Cardiac hypertrophy: A risk factor for QT-prolongation and cardiac sudden death. Toxicol Pathol 2006;34:58–66.
12. Schocken DD, Benjamin EJ, Fonarow GC et al. Prevention of heart failure: A scientific statement from the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation 2008;117:2544–2565.
13. Benzhi C, Limei Z, Ning W et al. Bone marrow mesenchymal stem cells upregulate transient outward potassium currents in postnatal rat ventricular myocytes. J Mol Cell Cardiol 2009;47:41–48.
14. Shen Q, Goderie SK, Jin L et al. Endothelial cells stimulate self-renewal and expand neurogenesis of neural stem cells. Science 2004;304: 1338–1340.
15. Yamada Y, Yokoyama S, Wang XD et al. Cardiac stem cells in brown adipose tissue express CD133 and induce bonemarrow nonhematopoietic cells to differentiate into cardiomyocytes. STEM CELLS 2007;25:1326–1333.
16. Ellison GM, Torella D, Karakikes I et al. Acute beta-adrenergic overload produces myocyte damage through calcium leakage from the ryanodine receptor 2 but spares cardiac stem cells. J Biol Chem 2007;282:11397–11409.
17. Dong DL, Chen C, Huo R et al. Reciprocal repression between microRNA-133 and calcineurin regulates cardiac hypertrophy: A novel mechanism for progressive cardiac hypertrophy. Hypertension 2010;55:946–952.
18. Lin Z, Murtaza I, Wang K et al. miR-23a functions downstream of NFATc3 to regulate cardiac hypertrophy. Proc Natl Acad Sci USA 2009;106:12103–12108.
19. Shan H, Li X, Pan Z et al. Tanshinone IIA protects against sudden cardiac death induced by lethal arrhythmias via repression of microRNA-1. Br J Pharmacol 2009;158: 1227–1235.
20. Houser SR, Molkentin JD. Does contractile Ca2+ control calcineurin-NFAT signaling and pathological hypertrophy in cardiac myocytes? Sci Signal 2008;1:pe31.
21. Wilkins BJ, De Windt LJ, Bueno OF et al. Targeted disruption of NFATc3, but not NFATc4, reveals an intrinsic defect in calcineurinmediated cardiac hypertrophic growth.MolCell Biol 2002;22:7603–7613.
22. Crabtree GR. Generic signals and specific outcomes: Signaling through Ca2+, calcineurin, and NF-AT. Cell 1999;96:611–614.
23. Gnecchi M, He H, Liang OD et al. Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med 2005;11:367–368.
24. Uemura R, Xu M, Ahmad N et al. Bone marrow stem cells prevent left ventricular remodeling of ischemic heart through paracrine signaling. Circ Res 2006;98:1414–1421.
25. Xu M, Uemura R, Dai Y et al. In vitro and in vivo effects of bone marrow stem cells on cardiac structure and function. J Mol Cell Cardiol 2007;42:441–448.
26. Rissanen TT, Markkanen JE, Gruchala M et al. VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses. Circ Res 2003;92:1098–1106.
27. Amado LC, Saliaris AP, Schuleri KH et al. Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction. Proc Natl Acad Sci USA 2005;102:11474–11479.
28. Ohnishi S, Yanagawa B, Tanaka K et al. Transplantation of mesenchymal stem cells attenuates myocardial injury and dysfunction in a rat model of acute myocarditis. J Mol Cell Cardiol 2007;42:88–97.
29. Chang MG, Tung L, Sekar RB et al. Proarrhythmic potential of mesenchymal stem cell transplantation revealed in an in vitro coculture model. Circulation 2006;113:1832–1841.
30. Cho J, Zhai P, Maejima Y et al. Myocardial injection with GSK-3b-overexpressing bone marrow-derived mesenchymal stem cells attenuates cardiac dysfunction after myocardial infarction. Circ Res 2011;108:478–489.
31. Dai Y, Xu M, Wang Y et al. HIF-1alpha induced-VEGF overexpression in bone marrow stem cells protects cardiomyocytes against ischemia. J Mol Cell Cardiol 2007;42:1036–1044.
32. Li Y, Hiroi Y, Ngoy S et al. Notch1 in bone marrow-derived cells mediates cardiac repair after myocardial infarction. Circulation 2011; 123:866–876.
33. Zhao Y, Li T, Wei X et al. Mesenchymal stem cell transplantation improves regional cardiac remodeling following ovine infarction. STEM CELLS TRANSLATIONAL MEDICINE 2012;1:685–695.
34. Xu RX, Chen X, Chen JH et al. Mesenchymal stem cells promote cardiomyocyte hypertrophy in vitro through hypoxia-induced paracrine mechanisms. Clin Exp Pharmacol Physiol 2009;36:176–180.
35. Mignone JL, Murry CE. A repair “kit” for the infarcted heart. Cell Stem Cell 2011;8: 350–352.
36. Izumiya Y, Shiojima I, Sato K et al. Vascular endothelial growth factor blockade promotes the transition from compensatory cardiac hypertrophy to failure in response to pressure overload. Hypertension 2006;47: 887–893.
37. Gordon O, Gilon D, He Z et al. Vascular endothelial growth factor-induced neovascularization rescues cardiac function but not adverse remodeling at advanced ischemic heart disease. Arterioscler Thromb Vasc Biol 2012;32:1642–1651.
38. Shimojo N, Jesmin S, Zaedi S et al. Contributory role of VEGF overexpression in endothelin-1-induced cardiomyocyte hypertrophy. Am J Physiol Heart Circ Physiol 2007; 293:H474–H481.
39. Li H, Malhotra D, Yeh CC et al. Myocardial survival signaling in response to stem cell transplantation. J Am Coll Surg 2009;208:607–613.
40. Rolf A, Assmus B, Schächinger V et al. Maladaptivehypertrophy after acutemyocardial infarction positive effect of bone marrowderived stem cell therapy on regional remodeling measured by cardiac MRI. Clin Res Cardiol 2011;100:983–992.